Aripiprazole tablets with sensor offer a new wireless trackable form of aripiprazole that represents a clear departure from existing drug delivery systems, routes, or formulations. This tracking technology raises concerns about the ethical treatment of patients with psychosis when it could introduce unintended treatment challenges. The use of "trackable" pills and other "smart" drugs or nanodrugs assumes renewed importance given that physicians are responsible for determining patients' decision-making capacity. Psychiatrists are uniquely positioned in society to advocate on behalf of vulnerable patients with mental health disorders. The case presented here focuses on guidance for capacity determination and informed consent for such nanodrugs.
|Number of pages||5|
|Journal||AMA Journal of Ethics|
|State||Published - Apr 2019|